COL4A3 and Alport syndrome: Podocyte damage in animal models of non-diabetic disease such as the Col4a3 knockout model of Alport Syndrome prone to lipotoxicity showed that empagliflozin was protective of lipotoxicity-induced podocyte apoptosis (56).